The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in cash or US$624 million (approximately C$841 million) – a 120% premium over the closing price of just over US$18 a share before the deal was announced.The case also brings the reader up to date on the turns Anthony’s life has taken since the acquisition and some of the exciting ventures in which he is now involved.
Learning Objective
• Managing growth in a biopharma company
• Leadership in a pharma company, from start-up to listed firm and trade sale
• Developing resilience in a firm - Managing risk